Research News and Research

RSS

Chocolate for the heart - benefits revealed

A comprehensive analysis of previous studies including more than 114,000 subjects has shown that high levels of chocolate consumption are associated with a significant reduction in the risk of certain cardiovascular disorders.

30 Aug 2011

Roundup: Calif. ruling may extend mental health coverage; Conn. dropping early intervention program; Alaska clinic focuses on Medicare patients

A Northern California woman's treatment for anorexia at a residential facility was medically necessary and must be covered by her healthcare plan, a federal appeals court has ruled in a case that could lead to more extensive benefits for those being treated for mental illnesses.

30 Aug 2011

Governor Perry attacked for choosing new medical treatment

Recently, the governor of Texas and presidential hopeful had a bad back treated by injecting some of his very own fat cells, after they had been cultured and treated in a laboratory. The innovative use of a patient’s own adult stem cells is showing great promise in many conditions, including damaged joints.

29 Aug 2011

Student researchers throughout Australia compete for annual award

Student researchers from throughout Australia will compete for state and national titles in the country’s leading competition for life science, biotechnology and bio-engineering students: the 2011 AusBiotech-GSK Student Excellence Awards. Applications are now open for the 2011 awards.

29 Aug 2011

Optical treatment strategies to correct peripheral vision may slow progression of myopia

New scientific evidence on how feedback from the eye affects visual development may lead to more effective approaches to treating myopia (nearsightedness) in children, reports a paper in the September issue of Optometry and Vision Science, official journal of the American Academy of Optometry. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

29 Aug 2011

Adimab initiates independent collaborations with Biogen Idec and Novo Nordisk

Adimab, LLC, a technology leader in the discovery of fully human antibodies, today announced the initiation of two independent collaborations with Biogen Idec and Novo Nordisk. Over the past two years, Adimab has established collaborations with multiple leading pharmaceutical companies, including: Merck, Roche, Novartis, Pfizer, Eli Lilly, Genentech, Human Genome Sciences, and now Biogen Idec and Novo Nordisk.

29 Aug 2011

Curemark's novel compound CM-182 shows promise for treatment of hyperactivity without sedation

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that its compound CM-182 demonstrated positive results for reduction in hyperactivity in mice treated with amphetamines. The mouse model screening was performed by the contract research organization, Cerca Insights.

29 Aug 2011

Money alone cannot fix Russia's 'demographic crisis'

Russia "is in a demographic crisis, shedding 2.2 million people (or 1.6 percent of the population) since 2002, and the government is trying to encourage more women to bring Russian citizens into the world," journalist Natalia Antonova writes in a Foreign Policy opinion piece, in which she describes her experience with the Russian medical system after "unexpectedly" becoming pregnant shortly after receiving her visa to work in Moscow.

29 Aug 2011

Pfizer receives FDA approval of XALKORI for ALK-positive NSCLC

Pfizer Inc. has received FDA approval of XALKORI (crizotinib) capsules - the first and only therapy specifically for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

29 Aug 2011

Zymeworks, Merck collaborate to develop novel bi-specific antibody therapeutic candidates

Zymeworks Inc. today announced a research collaboration with Merck, known as MSD outside the United States and Canada, around Zymeworks' proprietary Azymetric platform for the development of novel bi-specific antibody therapeutic candidates. Bi-specific antibodies are designed to bind to two different drug targets for broad use in clinical applications such as oncology or autoimmune disease.

29 Aug 2011

Covalon reports net loss of $1,207,559 for third quarter 2011

Mr. Brian Pedlar, President and CEO of Covalon Technologies Ltd., an advanced medical technologies company, is pleased to provide the following update. "We are very pleased that Covalon continues to make excellent progress in meeting its objectives.

29 Aug 2011

GOP presidential hopeful Rick Perry on health issues

In analyzing Texas Gov. Rick Perry's health record, medical malpractice reform is one of the issues he appears to be most passionate about.

29 Aug 2011

New insights into Lafora disease

Short-term energy storage in animal cells is usually achieved through the accumulation of glucose, in the form of long and branched chains, known as glycogen. But when this accumulation happens in neurons it is fatal, causing them to degenerate. This neuronal deterioration and death associated with glycogen accumulation is the hallmark of an extremely rare and progressive type of epilepsy known as Lafora disease (LD).

29 Aug 2011

For NAIC, some signals suggest broker bill is losing traction

The Hill reports that a spokeswoman for the chairman of the NAIC's Professional Health Insurance Advisors Task Force said no major action on the issue was planned for the group's conference. In other news, MSNBC reports that, as insurance prices rise, options appear to diminish, creating questions about how much relief the health law will provide. Meanwhile, the Milwaukee Journal Sentinel explores health reform's winners and losers.

29 Aug 2011

CMS: Insurers need to create plans for dual eligibles

Medicare Advantage insurers that cover some of the most expensive patients must develop individualized plans to coordinate care for each one, according to a final CMS rule issued Friday. The agency also formalized language in the Affordable Care Act requiring these so-called Special Needs Plans, which handle the costly population covered by both Medicare and Medicaid, to implement quality improvement programs and be certified in 2012 by the National Committee for Quality Assurance.

29 Aug 2011

Men worse than women at protecting their skin in the sun

Nearly 90 per cent of British adults admit their skin has been sunburnt - with almost half experiencing pain as result of being in the sun.

29 Aug 2011

Kassebaum reflects on HIPAA's impact

[Nancy Landon] Kassebaum [Baker], the name she went by in the Senate as a three-term Republican from Kansas and before her marriage to former Sen. Howard Baker (R-Tenn.), was a co-sponsor along with Edward Kennedy (D-Mass.) of the Health Insurance Portability and Accountability Act. Kassebaum, now 79, is living with her husband in Huntsville, Baker's hometown in the Cumberlands of northeastern Tennessee.

29 Aug 2011

Disappearance of mosquitoes from some parts of Africa puzzles researchers

"Malaria-carrying mosquitoes are disappearing in some parts of Africa, ... indicat[ing] controls such as anti-mosquito bed nets are having a significant impact on the incidence of malaria in some sub-Saharan countries," researchers report in a paper published in Malaria Journal, according to BBC News. But the team of Danish and Tanzanian "researchers say mosquitoes are also disappearing from areas with few controls," and "[t]hey are uncertain if mosquitoes are being eradicated or whether they will return with renewed vigor," the news agency writes.

29 Aug 2011

Specific inhibitor of microRNA-100 can stimulate development of new blood vessels

A specific inhibitor of the small regulatory RNA-molecule "microRNA-100" can be used to stimulate the growth of new blood vessels, if a major artery is chronically occluded.

29 Aug 2011

European infusion therapy device market to reach €533 million by 2017: New report

According to a new report by iData Research, the leading global authority in medical device market research, the European infusion therapy device market, which includes needleless connectors, infusion pumps and intravenous (IV) sets, was valued at an estimated €443 million in 2010.

29 Aug 2011